search
Back to results

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Primary Purpose

Essential Arterial Hypertension

Status
Withdrawn
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Candesartan + Chlorthalidone (8mg+12,5mg)
Candesartan + Chlorthalidone (8 mg + 25 mg)
losartan+hydrochlorothiazide
Sponsored by
EMS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Essential Arterial Hypertension

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed Consent of the patient;
  • Participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian Society of Cardiology (2010), who have never been treated and have indication for drug combination treatment.

Obs: The diagnosis may be established by previous evaluation of two blood pressure measures ≥ 140/90 mmHg, with two months difference between measurements

Exclusion Criteria:

  • Patients with any clinically significant disease that in the investigator is opinion can not participate in the study;
  • Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the screening/randomization visit;
  • Morbid obesity or immunocompromised patients;
  • Participants with greater than 10 mmHg difference in the measurements of systolic or diastolic blood pressure between the two arms;
  • Participants who do not have the two upper limbs;
  • Participants with important electrocardiographic changes;
  • Creatinine clearance - less than 60 mL /min;
  • History of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months;
  • Microalbuminuria in urine sample greater than 30 mg/g;
  • Patients with history of hypersensitivity to any of the formula compounds;
  • Pregnancy or risk of pregnancy and lactating patients;
  • Participation in clinical trial in the year prior to this study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Active Comparator

    Arm Label

    Test 1: Candesartan + Chlorthalidone

    Test 2: Candesartan + Chlorthalidone

    Comparator: losartan+hydrochlorothiazide (Hyzaar®)

    Arm Description

    The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.

    The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.

    he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.

    Outcomes

    Primary Outcome Measures

    Efficacy of essential hypertension control based on proportion of participants who achieve the therapeutic goal

    Secondary Outcome Measures

    Safety will be evaluated by the occurrences of adverse events.

    Full Information

    First Posted
    August 10, 2015
    Last Updated
    January 17, 2017
    Sponsor
    EMS
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02521233
    Brief Title
    Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
    Official Title
    Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2017
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Sponsor decision
    Study Start Date
    November 2016 (undefined)
    Primary Completion Date
    May 2017 (Anticipated)
    Study Completion Date
    August 2017 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    EMS

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Essential Arterial Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Test 1: Candesartan + Chlorthalidone
    Arm Type
    Experimental
    Arm Description
    The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.
    Arm Title
    Test 2: Candesartan + Chlorthalidone
    Arm Type
    Experimental
    Arm Description
    The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.
    Arm Title
    Comparator: losartan+hydrochlorothiazide (Hyzaar®)
    Arm Type
    Active Comparator
    Arm Description
    he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
    Intervention Type
    Drug
    Intervention Name(s)
    Candesartan + Chlorthalidone (8mg+12,5mg)
    Other Intervention Name(s)
    Candesartan + Chlorthalidone
    Intervention Type
    Drug
    Intervention Name(s)
    Candesartan + Chlorthalidone (8 mg + 25 mg)
    Other Intervention Name(s)
    Candesartan + Chlorthalidone
    Intervention Type
    Drug
    Intervention Name(s)
    losartan+hydrochlorothiazide
    Other Intervention Name(s)
    Hyzaar ®
    Primary Outcome Measure Information:
    Title
    Efficacy of essential hypertension control based on proportion of participants who achieve the therapeutic goal
    Time Frame
    60 days
    Secondary Outcome Measure Information:
    Title
    Safety will be evaluated by the occurrences of adverse events.
    Time Frame
    9 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Signed Consent of the patient; Participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian Society of Cardiology (2010), who have never been treated and have indication for drug combination treatment. Obs: The diagnosis may be established by previous evaluation of two blood pressure measures ≥ 140/90 mmHg, with two months difference between measurements Exclusion Criteria: Patients with any clinically significant disease that in the investigator is opinion can not participate in the study; Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the screening/randomization visit; Morbid obesity or immunocompromised patients; Participants with greater than 10 mmHg difference in the measurements of systolic or diastolic blood pressure between the two arms; Participants who do not have the two upper limbs; Participants with important electrocardiographic changes; Creatinine clearance - less than 60 mL /min; History of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months; Microalbuminuria in urine sample greater than 30 mg/g; Patients with history of hypersensitivity to any of the formula compounds; Pregnancy or risk of pregnancy and lactating patients; Participation in clinical trial in the year prior to this study.

    12. IPD Sharing Statement

    Learn more about this trial

    Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

    We'll reach out to this number within 24 hrs